New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:19 EDTJNJ, CG, RBGPFJohnson & Johnson sees deal to sell K-Y brand to Reckitt closing mid-year
Sees sees deal to sell K-Y brand to Reckitt Benckiser (RBGPF) closing mid-year. Says offer from Carlyle Group (CG) to acquire Ortho-Clinical Diagnostics expected to close mid-year. Comments from slides that will be presented on the Q1 earnings conference call.
News For JNJ;RBGPF;CG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
18:59 EDTCGCarlyle Group in talks for 37% stake in Metropolis Health, Times of India says
Carlyle Group is in advanced discussions to purchase a 37% stake in Metropolis Healthcare for RS900 crore, reports Times of India, citing people directly familiar with the matter. Sources said a deal could be reached within the next few weeks. Reference Link
16:33 EDTJNJGilead submits NDA to FDA for single tablet regimen for HIV containing R/F/TAF
Gilead Sciences (GILD) announced that it has submitted a New Drug Application, or NDA, to the FDA for an investigational, once-daily single tablet regimen that combines Gileadís emtricitabine 200 mg and tenofovir alafenamide, or TAF, 25 mg with rilpivirine 25 mg, or R/F/TAF, from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naÔve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen. A Priority Review voucher acquired from Knight Therapeutics in November 2014 was submitted to the FDA along with the R/F/TAF NDA. Under the Prescription Drug User Fee Act, or PDUFA, the anticipated target action date for the R/F/TAF NDA is six months after the FDAís acceptance of the filing. TAF is a novel, investigational nucleotide reverse transcriptase inhibitor, or NRTI, that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gileadís Viread, as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials in combination with other antiretroviral agents. In addition to R/F/TAF, two other TAF-based HIV treatments are also under FDA review.
June 29, 2015
06:07 EDTCGBMW, Macquarie expected to bid for ANZ Banking unit, Reuters reports
According to a source familiar of the situation, BMW and Macquarie Group are among the companies expected to make a bid for Australia and New Zealand Banking Group's car and equipment loan book, Reuters reports. Additionally, buyout firms Carlyle (CG), Blackstone (BX) and TPG have requested information memorandums for the sale. The unit could fetch more than the $6.35B book value of the loans, the source says. Reference Link
June 28, 2015
17:44 EDTCGCarlyle Group to invest $120M in Shanghai ANE Logistics
The Carlyle Group announced that it has agreed to invest approximately $120M into Shanghai ANE Logistics. The transaction is expected to close in Q3. Equity for the transaction will come from Carlyle Asia Partners IV.
June 22, 2015
07:55 EDTCGSotherly Hotels agrees to acquire remaining interest in Crowne Plaza Hollywood
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use